These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 27981572)

  • 1. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.
    Moriyama B; Obeng AO; Barbarino J; Penzak SR; Henning SA; Scott SA; Agúndez J; Wingard JR; McLeod HL; Klein TE; Cross SJ; Caudle KE; Walsh TJ
    Clin Pharmacol Ther; 2017 Jul; 102(1):45-51. PubMed ID: 27981572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision?
    Zhong X; Tong X; Ju Y; Du X; Li Y
    Curr Drug Metab; 2018; 19(14):1152-1158. PubMed ID: 29361899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
    Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
    Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective CYP2C19-Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations.
    Hicks JK; Quilitz RE; Komrokji RS; Kubal TE; Lancet JE; Pasikhova Y; Qin D; So W; Caceres G; Kelly K; Salchert YS; Shahbazian K; Abbas-Aghababazadeh F; Fridley BL; Velez AP; McLeod HL; Greene JN
    Clin Pharmacol Ther; 2020 Mar; 107(3):563-570. PubMed ID: 31549389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.
    Hicks JK; Sangkuhl K; Swen JJ; Ellingrod VL; Müller DJ; Shimoda K; Bishop JR; Kharasch ED; Skaar TC; Gaedigk A; Dunnenberger HM; Klein TE; Caudle KE; Stingl JC
    Clin Pharmacol Ther; 2017 Jul; 102(1):37-44. PubMed ID: 27997040
    [No Abstract]   [Full Text] [Related]  

  • 6. Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation.
    Teusink A; Vinks A; Zhang K; Davies S; Fukuda T; Lane A; Nortman S; Kissell D; Dell S; Filipovich A; Mehta P
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):482-6. PubMed ID: 26616742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
    Hamadeh IS; Klinker KP; Borgert SJ; Richards AI; Li W; Mangal N; Hiemenz JW; Schmidt S; Langaee TY; Peloquin CA; Johnson JA; Cavallari LH
    Pharmacogenet Genomics; 2017 May; 27(5):190-196. PubMed ID: 28306618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invasive Aspergillus infection requiring lobectomy in a CYP2C19 rapid metabolizer with subtherapeutic voriconazole concentrations.
    Hicks JK; Gonzalez BE; Zembillas AS; Kusick K; Murthy S; Raja S; Gordon SM; Hanna R
    Pharmacogenomics; 2016 May; 17(7):663-7. PubMed ID: 27143031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of Adverse Events and Determinants of the Voriconazole Trough Concentration in Kidney Transplantation Recipients.
    Zhao YC; Lin XB; Zhang BK; Xiao YW; Xu P; Wang F; Xiang DX; Xie XB; Peng FH; Yan M
    Clin Transl Sci; 2021 Mar; 14(2):702-711. PubMed ID: 33202102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients.
    Lin XB; Li ZW; Yan M; Zhang BK; Liang W; Wang F; Xu P; Xiang DX; Xie XB; Yu SJ; Lan GB; Peng FH
    Br J Clin Pharmacol; 2018 Jul; 84(7):1587-1597. PubMed ID: 29607533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort.
    Trubiano JA; Crowe A; Worth LJ; Thursky KA; Slavin MA
    J Antimicrob Chemother; 2015 Apr; 70(4):1161-5. PubMed ID: 25558073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retrospective study in Indians.
    Chawla PK; Nanday SR; Dherai AJ; Soman R; Lokhande RV; Naik PR; Ashavaid TF
    Int J Clin Pharm; 2015 Oct; 37(5):925-30. PubMed ID: 26024717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Observational Study of Associations between Voriconazole Therapeutic Drug Monitoring, Toxicity, and Outcome in Liver Transplant Patients.
    Hashemizadeh Z; Badiee P; Malekhoseini SA; Raeisi Shahraki H; Geramizadeh B; Montaseri H
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of CYP2C19 *17/*17 Genotype With the Risk of Voriconazole-Associated Squamous Cell Carcinoma.
    Williams K; Arron ST
    JAMA Dermatol; 2016 Jun; 152(6):719-20. PubMed ID: 26982740
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.
    Lee J; Ng P; Hamandi B; Husain S; Lefebvre MJ; Battistella M
    Ann Pharmacother; 2021 Apr; 55(4):509-529. PubMed ID: 32772568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of CYP2C19 Genotype-Guided Voriconazole Prophylaxis After Allogeneic Hematopoietic Cell Transplant.
    Patel JN; Hamadeh IS; Robinson M; Shahid Z; Symanowski J; Steuerwald N; Hamilton A; Reese ES; Plesca DC; Arnall J; Taylor M; Trivedi J; Grunwald MR; Gerber J; Ghosh N; Avalos B; Copelan E
    Clin Pharmacol Ther; 2020 Mar; 107(3):571-579. PubMed ID: 31549386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections.
    Lamoureux F; Duflot T; Woillard JB; Metsu D; Pereira T; Compagnon P; Morisse-Pradier H; El Kholy M; Thiberville L; Stojanova J; Thuillez C
    Int J Antimicrob Agents; 2016 Feb; 47(2):124-31. PubMed ID: 26775563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing.
    Dolton MJ; Mikus G; Weiss J; Ray JE; McLachlan AJ
    J Antimicrob Chemother; 2014 Jun; 69(6):1633-41. PubMed ID: 24554646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.
    Li ZW; Peng FH; Yan M; Liang W; Liu XL; Wu YQ; Lin XB; Tan SL; Wang F; Xu P; Fang PF; Liu YP; Xiang DX; Zhang BK
    Ther Drug Monit; 2017 Aug; 39(4):422-428. PubMed ID: 28604474
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.